<DOC>
	<DOC>NCT01335698</DOC>
	<brief_summary>The purpose of this study is to describe the safety, efficacy, and pharmacokinetics of a regimen of atazanavir powder boosted with ritonavir and an optimized dual nucleoside reverse transcriptase inhibitor in pediatric patients aged ≥3 months to &lt;11 years.</brief_summary>
	<brief_title>Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Key Confirmed HIV1 infection diagnosed by protocol criteria Screening HIV RNA level ≥1000 copies/mL ≥3 months to &lt;11 years of age at time of first treatment Antiretroviralnaive or experienced At screening, all participants must have genotypic sensitivity to atazanavir and at least 2 nucleoside reverse transcriptase inhibitors (NRTIs), which must be approved for pediatric use at the local country. Antiretroviralexperienced patients must also have documented phenotypic sensitivity at screening to atazanavir (Fold Change in susceptibility &lt;2.2) and to at least 2 NRTIs that are approved in their country Key Experienced participants who received atazanavir or atazanavir/ritonavir at any time prior to study enrollment or who have a history of 2 or more protease inhibitor failures Antiretroviralnaïve or experienced HIV1infected patients with contraindication to study medications Cardiac rhythm abnormalities Need for tenofovir Weight &lt;5 or ≥35kg &gt;Grade 2 abnormality in aspartate transaminase/alanine transaminase levels Coinfection with either hepatitis B or C virus Any active Centers for Disease Control and Prevention Category C clinical condition</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pediatric</keyword>
</DOC>